Overview

Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis

Status:
Recruiting

Trial end date:
2022-03-02

Target enrollment:

Participant gender:

Summary

This is a prospective, randomized clinical trial looking to determine the role of prophylactic treatment with topical corticosteroids in preventing recurrences in patients with a history of infectious epithelial keratitis, stromal keratitis,endotheliitis, or iridocyclitis. Patients will be enrolled to one of two treatment arms: Control arm: oral acyclovir 400 mg BID OR valacyclovir 500 mg daily or Study arm: oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops.

Phase:

Phase 4

Details

Lead Sponsor:

New York University School of Medicine
NYU Langone Health

Treatments:

Acyclovir
Antiviral Agents
Ophthalmic Solutions
Valacyclovir